Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lung cancer].

R M Huber1

  • 1Pneumologie, Klinikum der Universität - Innenstadt, Ziemssenstrasse 1, 80336 München, Germany. pneumologie@med.uni-muenchen.de

Der Internist
|June 13, 2006
PubMed
Summary
This summary is machine-generated.

Lung cancer, a leading global cause of cancer death, is categorized into small cell (SCLC) and non-small cell (NSCLC) types. Current treatments show limited success, necessitating further research and patient participation in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of lung adenocarcinoma-specific exosome RNAs in peripheral blood by RNA-Seq analysis.

European review for medical and pharmacological sciences·2020
Same author

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).

Lung cancer (Amsterdam, Netherlands)·2016
Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

[ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)].

Pneumologie (Stuttgart, Germany)·2016
Same author

[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

Der Pathologe·2016
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Context:

  • Lung cancer is the most common malignancy and leading cause of cancer mortality globally.
  • Smoking is the primary etiological factor.
  • Early detection remains challenging due to a lack of specific symptoms.

Purpose:

  • To provide an overview of lung cancer classification, staging, and current therapeutic strategies.
  • To highlight the limitations of existing treatments and the need for further research.

Summary:

  • Lung cancer is classified into small cell (SCLC) and non-small cell (NSCLC) for therapeutic purposes.
  • Staging follows the international TNM system.
  • Treatment strategies vary by type and stage, including polychemotherapy for SCLC, and chemo-radiotherapy or adjuvant chemotherapy for NSCLC.

Related Experiment Videos

  • Despite advances, outcomes remain suboptimal, emphasizing the importance of prospective trials.

    • Impact:

    • Informs clinicians and researchers about the current landscape of lung cancer management.
    • Underscores the critical need for improved therapeutic interventions and patient enrollment in clinical studies.
    • Contributes to the ongoing effort to reduce lung cancer morbidity and mortality worldwide.